Navigation Links
EASL-AASLD Special Conference on Therapy of Hepatitis C

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of:

Therapy of Hepatitis C: Clinical Application and Drug Development

During the three days of the conference held from 14-16 September 2012 in Prague, Czech Republic leading international Hepatitis C experts will highlight and address a series of lectures, and participate in interactive debates on hop topics in Hepatitis C. Case presentations and parallel interactive sessions will take place and space will be reserved for poster presentations of original works in the field.

The EASL-AASLD Special Conference provides an opportunity to keep abreast of the latest developments in this rapidly advancing field. The programme has been designed to provide adequate time for discussion and networking and will address a variety of areas including:

  • Global scale intervention and control of HCV
  • Prospects for a preventive HCV vaccine
  • Review of new drug treatments in development such as Nonnucleoside inhibitors of HCV RNA polymerase, NS5A inhibitors, and Cyclophylin inhibitors
  • Effectiveness of triple combinations in cirrhotics

Prof. Dr. Heiner Wedemeyer, a former EASL Secretary General and one of the Special Conference organisers, said a major discussion point at the conference will deal with the real-world use of new direct-acting antivirals (DAAs):

"We will discuss how to manage the side-effects of DDAs in real-world settings, and also their efficacy in populations not treated in pivotal registration trials. This is extremely important for physicians who are starting to use the drugs, particularly in terms of which patients should now be treated," said Prof. Dr. Heiner Wedemeyer.

Moreover, Prof. Dr. Wedemeyer said perspectives on Interferon (IFN) free treatment regimens will be extremely exciting: "After more than 25 years, we can now develop therapies that will not require IFN-alpha, which causes many side-effects and is also very expensive. We are experiencing a paradigm shift in the therapy of hepatitis C. This conference will also be very important for the development of new guidelines in Europe!"


Contact: Travis Taylor
European Association for the Study of the Liver

Related medicine news :

1. High Blood Pressure May Be Especially Lethal for Blacks
2. Internal medicine physician specialists release policy paper on reforming Medicaid
3. Being left out puts youths with special needs at risk for depression
4. Gastroenterology special issue focuses on new directions of viral hepatitis care and research
5. Specialized care by experienced teams cuts death and disability from bleeding brain aneurysms
6. Prenatal exposure to pollution especially dangerous for children with asthma
7. Hospital volume and surgeon specialty influence patient outcomes
8. Ethics should drive health policy reform, especially with physician-owned specialty hospitals
9. U.S.A. Hurdle Specialist Kellie Wells has Joined Elite Athletes Tiger Woods, Hines Ward and Takaishi Saito in Using Cell Therapy
10. Nassau County’s Special Districts and Service Providers Mapped for the First Time
11. Elsevier organizes label-free technologies conference
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... Tympani Inc., announced today that it ... Cisco. This designation recognizes Tympani as having fulfilled the training requirements and program ... the high-end enterprise contact center marketplace. , Ed Kapelinski, President of Tympani stated, ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of ... into its VIP Woman of the Year Circle. She is recognized with this ... exclusively for professional women, boasting 850,000 members and over 200 operating Local Chapters. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Being a caregiver ... the VA Maryland Health Care System, the Caregiver Support Program promotes the health ... a difficult job. Seventy-four percent report that their role as a caregiver has ...
(Date:11/30/2015)... TX (PRWEB) , ... November 30, 2015 , ... ... plastic surgery and dermatology, is proud to announce that its ThermiRFR temperature controlled ... , ThermiRF is an innovative multi-application radiofrequency platform which uses temperature as a ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... and fun atmosphere for Halloween festivities, the Word of Life Christian Church of ... board game, and featuring a giant 1.25 ton pile of candy dubbed “Candy ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 /PRNewswire/ ... its wholly-owned UK subsidiary Proximagen Ltd., today announced a ... oral small molecule inhibitor of Vascular Adhesion Protein 1 ... the treatment of inflammatory disease. The VAP-1 inhibitor is ... --> --> Under the terms of ...
(Date:11/30/2015)... TOKYO , 1 décembre 2015 ... plus grande exposition et conférence d,Asie ... médicaux et sur l,industrie manufacturière, se ... du 20 au 22 avril ... - Photo - ...
(Date:11/30/2015)... 2015 --> ... - Pipeline Review, H2 2015" market research ... pipeline of Endometriosis and helps enhance decision ... to gain competitive advantage. It strengthens R&D ... to produce first-in-class and best-in-class products. ...
Breaking Medicine Technology: